Not all oncology patients with actionable biomarkers are being identified, subjecting these patients to suboptimal treatment. But scientific advances have transformed the diagnostic landscape; when oncologists initiate comprehensive genomic profiling (CGP) of solid tumors by leading with liquid biopsy, they…Forty-five percent of patients with non-small cell lung cancer (NSCLC) now have actionable driver mutations.1 KRAS is the most frequently mutated oncogene in human cancers, and of all KRAS driver-mutations, KRAS G12C is the most common.2 The FDA…Targeted cancer therapies are prolonging patient survival times and improving quality of life,1 outcomes which are facilitated by tumor mutation profiling.2 Because cancer genomes are complex, comprehensive genomic profiling (CGP) offers the greatest insight into optimal treatment. In…Time is of the Essence For patients diagnosed with late-stage cancer, the longer treatment is delayed, the poorer the clinical prognosis,1-4 yet capturing a comprehensive picture of the disease is essential for determining the most appropriate first-line treatment. This…